Global Major Depression Epidemiology and Patient Flow Analysis - 2017

Global Major Depression Epidemiology and Patient Flow Analysis - 2017

  • January 2017 •
  • Report ID: 4835050 •
  • Format: PDF
Fore Pharma announced the results of its Major Depression patients study in a new report ‘Global Major Depression Epidemiology and Patient Flow Analysis - 2017’.

The report provides insights into Major Depression epidemiology, Major Depression diagnosed patients, and Major Depression treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Major Depression derived from epidemiological analysis, percentage of patients diagnosed with Major Depression, and percentage of patients treated with a therapy.

The study helps executives estimate Major Depression market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Major Depression prevalence, Major Depression diagnosis rate, and Major Depression treatment rate for the period 2016 - 2025. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.

Key Features of the Report:
- Major Depression Patient Flow
- Major Depression Prevalence
- Major Depression Diagnosed Patients
- Major Depression Treated Patients